Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
Recommended Citation
Oshima A, Imamura T, Narang N, Kinugawa K. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate. Clin Cardiol. 2021;44(9):1272-1275. doi:10.1002/clc.23683
Abstract
BACKGROUND: Sodium zirconium cyclosilicate (SZC), a newly-developed selective potassium binder, has been clinically available to treat hyperkalemia. SZC might be a promising option to manage hyperkalemia, particularly in patients with heart failure, who often require potassium-sparing medications. However, the optimal initial dose of SZC therapy at a loading dose (30 g per day for the initial 2 days) versus a maintenance dose (5 g per day) remains unknown.
METHODS: Consecutive patients with heart failure and hyperkalemia who received 2-day SZC therapy were retrospectively included. Safety and efficacy of SZC therapy were compared between the two strategies (maintenance versus loading).
RESULTS: We had 16 patients (76 years old, 11 men) who received 2-day SZC therapy (4 maintenance dose group and 12 loading dose group). Serum potassium decreased 0.7 mEqL/L by 2-day maintenance dose therapy and 1.3 mEq/L by 2-day loading dose therapy. Following 2-day SZC therapy, 25% of patients had hypokalemia, which was defined as serum potassium
CONCLUSIONS: SZC immediately decreases approximately 1.0 mEq/L of serum potassium in patients with heart failure and hyperkalemia. However, caution should be exercised when utilizing SZC at a loading dose specifically in those with mild hyperkalemia to prevent iatrogenic hypokalemia.
Document Type
Article
PubMed ID
34263946
Affiliations
Advocate Christ Medical Center